Wall Street Analysts Believe CureVac N.V. (CVAC) Could Rally 139%: Here's is How to TradeZacks Investment Research • 11/22/22
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business UpdateAccesswire • 11/16/22
CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102Accesswire • 11/11/22
CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022Accesswire • 11/10/22
Here's Why CureVac N.V. (CVAC) is Poised for a Turnaround After Losing 20.9% in 4 WeeksZacks Investment Research • 08/29/22
CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business UpdateAccesswire • 08/18/22
CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine CandidateAccesswire • 08/18/22
Wall Street Analysts Predict a 96% Upside in CureVac N.V. (CVAC): Here's What You Should KnowZacks Investment Research • 07/11/22
BioNTech stock falls after CureVac files suit, saying COVID vaccine infringes patentsMarket Watch • 07/05/22
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery PlatformAccesswire • 06/08/22
Wall Street Analysts See a 53% Upside in CureVac N.V. (CVAC): Can the Stock Really Move This High?Zacks Investment Research • 05/31/22
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine DevelopmentAccesswire • 05/25/22
Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business UpdateAccesswire • 05/25/22
CureVac NV (CVAC) CEO Franz-Werner Haas on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/28/22
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business UpdateAccesswire • 04/28/22